in clinical studies. Unfortunately, no standard regimen has been determined for CSCLC; therefore, its treatment mainly refers to the therapeutic regimens of pure SCLC, such as etoposidecarboplatin/cisplatin (EP/CE) 8 . However, CSCLC often yields poor prognosis because the combined NSCLC components may be insensitive to such chemotherapy regimens. Given that the majority of combined components of CSCLC were Ad 8, 10, 11 . Zhu et al. 12 added paclitaxel to the EP/CE regimen, thereby forming paclitaxel-etoposide-carboplatin/cisplatin (TEP/TCE) regimen for CSCLC. Nevertheless, a consensus on whether the efficiency and security of TEP/TCE regimen is superior to the standard EP/CE regimen remains unclear. The present retrospective study included 62 CSCLC patients, who were diagnosed pathologically. These patients underwent complete follow-up sessions and received initial treatment at the Tianjin Medical University Cancer Institute and Hospital from July 2006 to April 2013. On the basis of the chemotherapy regimens administrated, 62 patients were classified into two-drug group (receiving EP/CE regimen) and three-drug group (receiving TCE/TEP regimen) to compare the tumor response, survival benefits, and adverse effects of the two groups.
Materials and methods

Eligibility of patients
A total of 62 primary CSCLC patients who were treated at the Cancer Hospital of Tianjin Medical University from July 2006 to April 2013 were enrolled in this study. The following inclusion criteria were applied: (I) patients were diagnosed with CSCLC, which was confirmed via pathology or cytology; (II) patients were previously naive to chemotherapy, radiotherapy, or surgery; (III) patients exhibited no other malignancies; (IV) the lesions of patients can be evaluated via imaging; (V) their ages ranged from 34-79, and Karnofsky Performance Status (KPS) score was ≥60; (VI) the results of their blood, routine urine, electrolyte, liver function, kidney function, and electrocardiogram tests were within normal range; (VII) patients underwent complete follow-up sessions.
Chemotherapy
The 
Evaluation of response
CT or MRI scan was performed to evaluate tumor response every two chemotherapeutic cycles and at the end of treatment. Patients were examined monthly within 3 months after the end of treatment, every 2 months within 1 year after the end of treatment, and every 3-6 months thereafter. Unidirectional measurements were conducted in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 to evaluate short-term effects. Following the RECIST1.1, tumor response to treatment was classified as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).
Objective response rate (ORR) was defined as the proportion of patients evaluated as CR and PR, whereas disease control rate (DCR) was calculated as the proportion of patients evaluated as CR, PR, and SD. Overall survival (OS) was defined as the time from the start of treatment until death caused by any cause or until the last follow-up date. Moreover, progression-free survival (PFS) was defined as the time from the start of treatment to disease progression or death.
Toxicity
Chemotherapy-related adverse reactions were divided into five degrees (0-IV) based on the WHO classification of acute and subacute toxicity performance and indexing standards.
Statistical analysis
Statistical analyses were performed with SPSS 13.0. A P value ≤0.05 was considered statistically significant. Kaplan-Meier method was used to estimate the PFS and OS. Multivariate analysis of the prognostic factors was performed using Cox's regression model. Categorical variables were analyzed via χ 2 test, and measurement data were analyzed using t-test.
Results
A total of 540 CSCLC patients existed in 2,371 SCLC cases; thus, the incidence of CSCLC was 22.78%. Finally, we collected the data of 62 CSCLC patients who have met our inclusion criteria. Among 62 CSCLC patients, 49 were males and 13 were females, and the ratio of male patients to female patients was 3.85:1. The age of patients ranged from 34-79 years old, and the median age was 60. Smoking history was confirmed in 51 cases. In accordance with TNM staging, 5 patients were categorized in stage I, 5 patients were in stage II, and 52 patients were in advanced stage (25 patients were in stage III and 27 patients were in stage IV). The two chemotherapy regimen groups showed no significant differences in the baseline data ( Table 1) .
A total of 15 patients at stages I, II, and IIIa (T 1-3 N 2 M 0 ) received surgery and adjuvant chemotherapy with 3-drug regimen or 2-drug regimen. Other patients received radiation (Figures 1,2) . However, stratified analysis indicated that in patients with stages III and IV CSCLC, the median PFS nearly reached a statistical difference between the TEP/TCE and EP/CE groups (19.5 vs. 7.6 months, (Figures 3,4) . However, no significant difference existed between the two groups at stages I and II (Figures 5,6 ).
Univariate analysis
The results showed that patients with KPS score ≤80, distant metastasis, lymph node metastasis, and tumors at stages III and IV displayed poor prognosis (P<0.001, P=0.005, 0.032, and 0.001, respectively). Furthermore, the absence of surgery and prophylactic cranial irradiation (PCI) were considered adverse prognostic factors (P=0.009, 0.042). However, age, gender, smoking index, tumor size, number of chemotherapy cycles, thoracic radiotherapy, second-/third-line therapy were not related to the prognosis ( Table 3) .
Multivariate analysis
A multivariate analysis of prognostic factors was performed using Cox's regression model. The results showed that the KPS score, lymph node metastasis, distant metastasis, and PCI were independent predictors of prognosis (P=0.015, 0.007, 0.007, and 0.034, respectively) ( Table 3) .
Safety evaluation
The common chemotherapy-related adverse reactions included bone marrow suppression, gastrointestinal reaction, hepatic and renal function lesions, and skin rash. Most of these reactions were slight and reversible. 
Discussion
CSCLC is currently defined by the WHO as a subset of SCLC, which not only exhibits the characteristics of small cell lung cancer, such as rapid growth and high malignant degree, but also displays the characteristics of NSCLC, such as chemotherapy resistance. Patients with CSCLC have demonstrated poor response to chemotherapy in previous studies 13, 14 . Researchers attributed this finding to the combined NSCLC components. Thus, they attempted to explore ideal chemotherapy regimens. Luo et al. 8 compared the efficacy and safety of vinorelbine, ifosfamide, and cisplatin (NIP) with EP in treating advanced CSCLC, and they concluded that the ORR, PFS, and OS of patients in the NIP group were slightly inferior than those of patients under traditional EP regimen (83.8% vs. 90.6%, P=0.170; 6 vs. 6.5 months, P=0.163; 10.8 vs. 10.4 months, P=0.935, respectively). The TEP/TCE regimen has been widely used for CSCLC treatment at the Tianjin Medical University Cancer Institute and Hospital since 2005, with the aim of increasing the dose intensity and coverage rate of antitumor spectrum. The incidence of CSCLC in this institution was 22.78%, which was consistent with the findings of previous reports 3, 4 . In our study, a large proportion of patients were male (79.03%), heavy smokers (61.29%), and beyond 60 years old, which also corresponded to the study conducted by Lu et al. 15 .
The ORRs of the TEP/TCE and EP/CE groups were 90% and 53%, respectively, which reached a significant difference (P=0.033, χ 2 =4.552). Furthermore, urgent problems that need to be solved. Ad is the most common combined component of CSCLC 8, 10, 11 and the effectiveness rate of paclitaxel combined with cisplatin in the treatment of NSCLC (including Ad) reached 22%-47% [16] [17] [18] [19] . Although taxane is good for NSCLC, whether this drug induces the same effect on NSCLC components of CSCLC is unknown. Wagner et al. 7 determined that the NSCLC and SCLC components of CSCLC shared an identical immunophenotype with prevalent expression of synaptophysin and CD56 and loss of 22q13. Fukui et al. 20 also determined that patients with CSCLC with Ad shared an identical EGFR mutation in both SCLC and Ad components. Thus, the current findings suggested that NSCLC components of CSCLC may be close to SCLC in biology, and two kinds of components may exhibit the homology of gene sequence. We used next-generation sequencing method to compare and analyze whether the gene expression of Ad components in CSCLC is different from NSCLC. We believe that the results of our study will clarify the correlation of SCLC components with NSCLC components in CSCLC and contribute to the selection of the optimal treatment for CSCLC.
In conclusion, EP/CE regimen remains the standard regimen for majority of patients with CSCLC. However, three-drug regimen may increase the curative effect of patients in advanced stage. Nevertheless, this investigation is a retrospective, small, and nonrandomized study. Thus, the results need to be further confirmed by large prospective clinical trials.
